Institutional and structural racism, those social inequities deeply engrained or built into a society, include policies and conditions that disadvantage a group. These factors, whether intended or not, create inequities, such as reduced funding for remote or under-resourced cancer care centers, poor or no insurance for patients, few people from under-resourced communities within health care, and low clinical trial participation by members of these communities. Additionally, unconscious or conscious bias from health care professionals compounds structural barriers. To address systemic disparities in cancer care and to deliver high-quality care to all patients, health systems and institutions must recognize those factors that create inequities within their community. Analyses use patient-level quality measures to identify institution-specific gaps, and disparities in care delivery and outcomes, and use systems-level factors related to race, ethnicity, sexual orientation, gender, insurance status, geography, and more. By respecting and welcoming opportunities for introspection, institutions and HCPs can change their organizations and practices to improve care and outcomes for everyone.
In this CME Outfitters OnDemand Webcast, expert faculty will discuss how structural inequities rooted within health systems impact members of historically marginalized groups. They will describe major health care barriers and outline how institutional analyses can help identify and rectify these disparities. Resources to improve health equity, including partnerships with organizations such as Project ECHO, will demonstrate how these programs can be implemented. Finally, opportunities for introspection within the health care systems will be presented.
At the end of this CME/CE activity, participants should be able to analyze causes of disparities in the quality and delivery of cancer care.
Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, nurse navigators, pharmacists, social workers, and case managers specializing in oncology, emergency medicine and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mitchell reports financial relationships with: Advisory Board: Corvus Pharmaceuticals, Inc. Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo Inc.
Dr. Florez reports the following financial relationships: Advisory board: AstraZeneca; DSI; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Pfizer Inc. Speakers Bureau: NeoGenomics
Dr. Rivers reports no financial relationships.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).